Younger adults with non-small cell lung cancer are substantially more likely than older patients to carry genetic alterations that can be matched with existing targeted therapies, according to a large international analysis of genomic and immune data from 14,246 patients. The findings, led in part by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, suggest that age is associated with broad differences in tumor biology—not simply with changes in the frequency of individual mutations. The study will be presented Sept. 14 at the 2026 World Conference on Lung Cancer in Seoul, Republic of Korea, offering new evidence that a patient’s age may provide important biological context when clinicians interpret molecular test results and select treatments.
In the analysis, nearly 58% of younger patients had guideline-recommended actionable alterations, compared with approximately 45% of patients aged 55 and older. An actionable alteration is a change in a cancer cell’s DNA or signaling machinery for which a therapy already exists or is supported by clinical guidelines. These changes can act as molecular “switches,” driving uncontrolled cell growth while also creating vulnerabilities that targeted medicines can exploit. Comprehensive genomic profiling allows clinicians to search for these drivers across many genes at once, rather than testing for only one or two abnormalities. The difference observed across age groups indicates that the likelihood of finding a treatment-relevant alteration may vary considerably over a patient’s lifetime.
The younger group was more likely to have alterations involving ALK, ROS1 and EGFR, three genes that can activate growth pathways in lung cancer and have become central to precision oncology. When these alterations are detected, patients may be offered inhibitors designed to block the abnormal proteins produced by the altered genes. EGFR inhibitors, for example, interfere with signals that encourage tumor cells to divide, while ALK and ROS1 inhibitors target abnormal fusion proteins created when sections of DNA become incorrectly joined. These therapies can produce substantial responses in selected patients, although resistance often develops as tumors evolve under treatment. Identifying the molecular driver at diagnosis is therefore critical for matching patients with the most appropriate first-line strategy and for planning later testing when the cancer changes.
Older patients displayed a different molecular profile. Their tumors were more likely to contain KRAS-related alterations, which affect one of the cell’s major growth-control networks. KRAS mutations can be difficult to treat because the protein operates inside the cell and was historically considered resistant to direct drug targeting. Newer inhibitors have begun to change that landscape for selected KRAS variants, but the clinical options remain dependent on the precise mutation and the tumor’s broader biology. The age-associated pattern seen in the study does not mean that every older patient has a KRAS alteration or that younger patients lack one. Instead, it describes a shift in probabilities across a large population, underscoring why individual tumors still require direct molecular testing.
The researchers also found that older patients tended to have a higher tumor mutational burden, or TMB. TMB estimates the number of DNA changes carried by a tumor and is sometimes used as one factor in evaluating whether a cancer may be more visible to the immune system. A high mutational burden can create abnormal proteins, known as neoantigens, that immune cells may recognize as foreign. However, TMB is not a standalone predictor of response to immunotherapy. The immune system’s ability to detect and attack a tumor depends on many additional features, including antigen presentation, immune-cell infiltration, tumor defenses and the surrounding microenvironment. The results therefore point to a complex contrast: older tumors may carry more mutations overall, while younger tumors may more often contain a single, therapeutically targetable driver.
Age-related differences were also observed in immune markers such as LAG3 and TIGIT. These molecules are found on immune cells and can participate in inhibitory signaling networks that restrain immune activity. Tumors may exploit such “checkpoint” pathways to weaken an immune response, and drugs aimed at these mechanisms are being investigated as potential components of future immunotherapy combinations. The presence or level of a marker does not automatically establish that blocking it will benefit a patient. Clinical responses depend on the interaction between tumor genetics, immune-cell states and the wider tumor microenvironment. Nonetheless, the findings suggest that age could help researchers design more precise studies of immunotherapy biology instead of treating all patients with non-small cell lung cancer as a single molecular population.
Chinmay T. Jani, M.D., a medical oncologist at Sylvester and the study’s lead author, said the results support looking beyond isolated mutations to understand the biological setting in which those alterations arise. Tumors are ecosystems shaped by accumulated genetic damage, tissue environment, immune pressure and the patient’s own biology. Those forces change over time, potentially influencing which cancer-driving events emerge and how the immune system responds to them. Gilberto Lopes, M.D., Sylvester’s chief of medical oncology, associate director and medical director for international affairs, and the study’s senior author, said age should be considered alongside traditional biomarkers when treatment options are evaluated. Such an approach could help physicians interpret borderline or complex test results more effectively, while avoiding the assumption that chronological age alone determines a tumor’s behavior.
The analysis also found similar age-related patterns across multiple ancestry groups, strengthening the possibility that the observations reflect biological trends rather than the characteristics of a single population. Even so, ancestry, environmental exposures, smoking history, sex, access to testing and other clinical variables can influence both lung cancer biology and the likelihood that a patient receives comprehensive profiling. The reported findings should therefore be viewed as population-level evidence rather than as a replacement for individualized assessment. A younger patient without an actionable alteration may still benefit from immunotherapy or chemotherapy, while an older patient may carry a highly targetable EGFR, ALK, ROS1 or other alteration. Molecular results, overall health, prior treatment, organ function and patient preferences remain essential to treatment decisions.
The study may have particular importance for younger adults, who generally fall outside current eligibility criteria for routine lung cancer screening. Screening recommendations are designed to balance the potential benefit of earlier detection against the harms of false positives, unnecessary procedures and radiation exposure. If younger patients can develop tumors with distinct molecular profiles despite not meeting standard screening thresholds, researchers may need to investigate additional ways to identify those at elevated risk. The new findings do not establish a screening policy or prove that age-specific testing would improve survival, but they add to the evidence that lung cancer is biologically diverse across the lifespan. They also reinforce the value of comprehensive genomic profiling after diagnosis, because a tumor’s most important treatment clue may be hidden among alterations that limited testing would miss.
For precision medicine, the central message is that the question is not only which mutation a tumor contains, but also why that mutation appears in a particular biological environment and how the cancer’s genomic and immune features interact. The investigators’ international dataset provides a broad foundation for future studies linking age, molecular drivers, immune phenotypes and treatment outcomes. The next step will be determining whether the observed differences predict responses to specific targeted therapies or immunotherapies, how they change as disease progresses, and whether age-informed models can improve clinical decisions without creating rigid treatment categories. As lung cancer care becomes increasingly dependent on molecular information, incorporating the biology of aging could help move the field toward more individualized therapies for patients across the entire adult age spectrum.
Subject of Research: Age-related genomic drivers and immune phenotypes in non-small cell lung cancer
Article Title: “Age and biomarkers: divergent genomic drivers and immune phenotypes across 14,246 real-world NSCLC patients”
News Publication Date: Aug. 20, 2026
Web References: Sylvester Comprehensive Cancer Center; 2026 World Conference on Lung Cancer presentation; InventUM blog
References: IASLC 2026 World Conference on Lung Cancer, Sept. 12–15, 2026; conference poster, “Age and biomarkers: divergent genomic drivers and immune phenotypes across 14,246 real-world NSCLC patients”
Image Credits: Sylvester Comprehensive Cancer Center
Keywords: lung cancer, non-small cell lung cancer, cancer genomics, precision medicine, targeted therapy, EGFR, ALK, ROS1, KRAS, tumor mutational burden, immunotherapy, cancer biomarkers, immune phenotypes, comprehensive genomic profiling
Tags: actionable genetic alterationsage and tumor biology in lung cancerage-related differences in lung cancer biologycancer mutation analysisgenetic mutations in non-small cell lung cancergenomic profiling in lung cancerimmune data in lung cancerinternational lung cancer studieslung cancermolecular testing in lung cancerpersonalized treatment for lung cancertargeted therapy for lung cancer
